Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protara TherapeuticsTARA -2.73%32 Quick Ratio is 15.69 as of Mar. 2026, which is 0% below its 10-year median of 15.70. GuruFocus rates TARA with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, Protara Therapeutics ranks better than 87.95% on this metric.
Protara Therapeutics (NAS:TARA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Protara Therapeutics Quick Ratio Related Terms
Protara Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Protara Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Protara Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protara Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protara Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Protara Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Protara Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protara Therapeutics (TARA) has a Quick Ratio of 15.69 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Protara Therapeutics and its competitors. This is near median its historical median of 15.70. Over the past decade, Protara Therapeutics' Quick Ratio has ranged from 0.23 to 58.13. According to the industry distribution chart, Protara Therapeutics ranks #170 out of 1411 companies in the Biotechnology industry, placing it in the top 12%.
Is Protara Therapeutics' Quick Ratio too high?
Protara Therapeutics' current Quick Ratio of 15.69 is near median its 10-year median of 15.70. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 58.13. The Biotechnology industry median Quick Ratio is 3.56. Protara Therapeutics' value of 15.69 is 340.7% above this industry median. Based on the distribution chart, Protara Therapeutics ranks #170 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Protara Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Protara Therapeutics' Quick Ratio compare to TRDA and ACIU?
According to the Biotechnology industry distribution chart, Protara Therapeutics ranks #170 out of 1411 companies for Quick Ratio. This places Protara Therapeutics in the top 12% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.56. Protara Therapeutics' value of 15.69 is 340.7% above this benchmark. Historically, Protara Therapeutics' own Quick Ratio has ranged from 0.23 to 58.13 over the past decade. While the company's 10-year median is 15.70 vs. the industry median of 3.56, Protara Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.56, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protara Therapeutics's current Quick Ratio of 15.69 is 340.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Protara Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protara Therapeutics's current Quick Ratio is 15.69, which is near median its own 10-year median of 15.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protara Therapeutics stock overvalued right now?
Protara Therapeutics (TARA) has a current Quick Ratio of 15.69. The current Quick Ratio is 15.69, which is near median its 10-year median of 15.70 and 340.7% above the Biotechnology industry median of 3.56. Protara Therapeutics' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Protara Therapeutics (TARA), the current Quick Ratio is 15.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
32GF Score
Get the complete analysis for TARA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TARA has been successfully added to your 
